We are improving the lives of people suffering from mental illness and substance use disorders

What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

 Discover our story 

Key News

SEPTEMBER 9, 2022
Orexo´s partner announces the result from the phase 2 study for OXMPI 

 

SEPTEMBER 7, 2022
Trinity Health announces the availability of vorvida® and deprexis® to patients

SEPTEMBER 1, 2022 
First patent issued for Orexo´s adrenaline product in Europe 

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).

MODIA® - our digital therapy for opioid dependence

  • to be used along with pharmaceuticals
  • 6 months treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. up to 400 patients

Orexo Social

23 September 2022

#Orexo looks forward to being part of the US Pavillion exhibition at NLS Days, Sep. 28-29. Along with our co-hosts,… https://t.co/NhMbJkltuo

19 September 2022

Klas Palin analytiker på Erik Penser Bank intervjuar Orexos VD om den senaste utvecklingen inom digitala behandlina… https://t.co/KVwvbximNk

16 September 2022

In 2013 #Orexo launched its lead product for opioid dependence on the US market. Since then, total net sales have r… https://t.co/aScs7f0yaw

Financial Snapshot

Group net revenues

597  MSEK

LTM1

Group EBITDA

-126 MSEK

LTM1

US Pharma segment EBIT

312 MSEK

LTM1

Cash position

468 MSEK

Q2 2022

1 Last Twelve Months, Q321-Q222, for more information about financial development Link